Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | PDE7A | Q13946 | 3/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 2/20 | 0.30 |
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | RECQL | P46063 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | MGLL | Q99685 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30168408 | 1.00 | MEN1 (0.38) | MEN1CYP2C9KMT2APDE4APDE4B | |
| SCHEMBL31459757 | 0.86 | HTR2A (0.35) | MEN1KMT2APDE7AHTR2AHTR2C | |
| SCHEMBL6898 | 0.86 | HTR2A (0.35) | MEN1KMT2APDE7AHTR2AHTR2C | |
| SCHEMBL8106440 | 0.82 | PDE7A (0.36) | MEN1KMT2APDE7AHTR2AHTR2C | |
| SCHEMBL1557008 | 0.81 | MEN1 (0.39) | MEN1CYP2C9KMT2APDE4APDE4B | |
| SCHEMBL12173556 | 0.81 | PDE7A (0.37) | MEN1KMT2APDE7AHTR2AHTR2C | |
| SCHEMBL2294184 | 0.80 | ADRA1A (0.43) | MEN1CYP2C9KMT2APDE4APDE4B | |
| SCHEMBL2288498 | 0.80 | ADRA1A (0.42) | MEN1CYP2C9KMT2APDE4APDE4B | |
| SCHEMBL3159094 | 0.80 | MEN1 (0.38) | MEN1CYP2C9KMT2APDE4APDE4B | |
| SCHEMBL7949441 | 0.80 | MEN1 (0.38) | MEN1CYP2C9KMT2APDE4APDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250179045-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | CONTINEUM THERAPEUTICS, INC. | 2025-06-05 | — | — | US | disclosed |
| WO-2023014907-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| WO-2023014907-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | Pipeline Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| EP-2303846-B1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | SANOFI SA (FR) | 2015-04-29 | — | — | EP | disclosed |
| EP-2303846-B1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | SANOFI SA (FR) | 2015-04-29 | — | — | EP | disclosed |
| US-8541449-B2 | Substituted isoquinolines and isoquinolinones as Rho kinase inhibitors | SANOFI (FR) | 2013-09-24 | — | — | US | disclosed |
| US-8541449-B2 | Substituted isoquinolines and isoquinolinones as Rho kinase inhibitors | SANOFI (FR) | 2013-09-24 | — | — | US | disclosed |
| US-8541449-B2 | Substituted isoquinolines and isoquinolinones as Rho kinase inhibitors | SANOFI (FR) | 2013-09-24 | — | — | US | disclosed |
| US-20110190341-A1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
| US-20110190341-A1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
| US-20110190341-A1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | SANOFI-AVENTIS (FR) | 2011-08-04 | — | — | US | disclosed |
| WO-2009156100-A1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | SANOFI-AVENTIS (FR) | 2009-12-30 | — | — | WO | disclosed |
| US-3979444-A | CENTRAL NERVOUS SYSTEM DEPRESSANTS, HYPOTENSIVES | THE UPJOHN COMPANY (US) | 1976-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190341-A1 | SUBSTITUTED ISOQUINOLINES AND ISOQUINOLINONES AS RHO KINASE INHIBITORS | ROCK1, MYLK, ROCK2 | MEN1 3398/4885CYP2C9 4327/4885KMT2A 2566/4885 |
| US-20250179045-A1 | LPAR1 ANTAGONISTS AND USES THEREOF | LPAR1, LPAR2, LPAR3 | MEN1 2811/4885CYP2C9 4402/4885KMT2A 2605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.